微信二维码

Exscientia announces multi-target, AI-driven drug discovery collaboration with B

  • 2021年05月19日
  • Author edit: mf123456

Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.

More ›

Biotech unicorn Oxford Nanopore Technologies has raised £195 million in new capi

  • 2021年05月11日
  • Author edit: mf123456

Oxford Nanopore Technologies, a next generation DNA/RNA sequencing technology company, recently has raise £195 million in new capital in a private transaction. £125 million of the investment comes from new investors Temasek, Wellington Management, M&G Investments and Nikon. In addition, existing shareholders invested £70 million.

More ›

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance N

  • 2021年05月06日
  • Author edit: mf123456

Boundless Bio Raises Oversubscribed $105 Million Series B Financing to Advance Next-Generation Precision Oncology Therapies Directed Against Extrachromosomal DNA (ecDNA) Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, announced the closing of an oversubscribed $105 Million Series B financing. With the proceeds of the financing, the company will advance into the clinic multiple ecDNA-directed therapeutic programs and the accompanying ecDNA Harboring Oncogenes (ECHO™) companion diagnostics and expand its pipeline of novel cancer therapies targeting ecDNA.

More ›

Exscientia, with its World’s first AI-Designed Immuno-Oncology Drug to Enter Cli

  • 2021年05月06日
  • Author edit: mf123456

Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round. SoftBank Vision Fund 2 led the Series D and was joined by previous round lead investors, Novo Holdings, GT Healthcare Capital and funds managed by Blackrock. Funding from the Series D round will be used to advance Exscientia’s proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design. In addition, SoftBank is providing an additional $300 million equity commitment that can be drawn at the Company’s discretion.

More ›

Exscientia completes Series C financing round with BlackRock funds

  • 2021年03月05日
  • Author edit:

Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. The existing Series C investors also include Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.

More ›